SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA concludes inspection of Biocon's insulin drug substance manufacturing facility

07 Mar 2019 Evaluate

US Food and Drug Administration (USFDA) has concluded a pre-approval inspection of Biocon's insulin drug substance manufacturing facility triggered by a New Drug Application (NDA).

The inspection at the Bengaluru facility took place on February 25 - March 05, 2019, resulting in a Form 483 with six observations.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

381.90 1.15 (0.30%)
07-May-2026 11:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1832.90
Dr. Reddys Lab 1307.40
Cipla 1366.80
Zydus Lifesciences 936.95
Lupin 2465.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×